Mometason Orion (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mometason Orion, is a corticosteroid presented as a nasal spray for nasal use. It reduces inflammation in the nasal passages of patients with allergic rhinitis and nasal polyps.

GNH USA supplies Mometason Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mometasone furoate nasal spray acts on inflammatory processes of the nasal mucosa to relieve symptoms of several upper‑respiratory conditions. - Allergic rhinitis: alleviates nasal congestion, itching and sneezing by decreasing mucosal inflammation. - Nasal polyps: shrinks polyp size and improves airflow through anti‑inflammatory action. - Seasonal allergic rhinitis: provides symptom control during pollen exposure by suppressing local immune response.

Mometasone furoate nasal spray may cause local and systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning sensation. - Epistaxis (nosebleeds). - Headache. - Sore throat. - Altered taste or unpleasant odor.

Serious or Rare Side Effects: - Nasal septal perforation. - Cataracts or glaucoma with prolonged use. - Adrenal suppression. - Opportunistic fungal infection of the nasal passages. - Severe hypersensitivity reactions such as angioedema.

Before using Mometasone furoate nasal spray, consider the following safety measures. - Pregnancy: consult a healthcare professional before use. - Breastfeeding: discuss potential risks with a physician. - Elderly patients: monitor for systemic corticosteroid effects. - Recent nasal surgery or trauma: postpone treatment until healing is complete. - Use only as directed: avoid exceeding recommended frequency. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mometasone furoate nasal spray can interact with other medicines; awareness helps prevent reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Systemic corticosteroids: may increase overall glucocorticoid exposure and risk of systemic effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise local drug concentrations.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask residual nasal symptoms, delaying assessment of effectiveness. - Decongestant nasal sprays: concurrent use can increase mucosal irritation. - Ritonavir or other protease inhibitors: may modestly elevate local steroid levels.